Atherosclerosis
An Introduction to Atherosclerosis
Atherosclerosis is defined as the build-up of plaque in the arteries, causing the narrowing of arteries and leading to the majority of heart attacks and strokes. Statin monotherapy has long been established as the gold-standard treatment, however the treatment landscape has grown over recent years with the introduction of new lipid-lowering therapies including fibrates, ezetimibe and PCSK-9 inhibitors. Further research and large-scale clinical trials are required to better compare their efficacy and safety with standard statin therapy.
Browse the content below where leading experts discuss the latest data in video interviews and short articles from our conference hub, and browse the selection of peer-reviewed articles from our journal portfolio. If you are looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.
Our supporting partners do not constitute an endorsement of the content on this page.
The touchCARDIO journal Heart International has once again seen an increase in its Journal Impact Factor (JIF), rising from 1.9 in 2024 to 2.3 in 2025.
This August, Boston will host one of the most influential gatherings in cardiovascular medicine as the American Society for Preventive Cardiology (ASPC) convenes its 2025 Congress on Cardiovascular Disease Prevention. Set for 1–3 August 2025 at the Omni Boston Hotel at the Seaport, Boston, MA, USA, the meeting will bring together global experts, showcase cutting-edge research, and feature more than 200 abstract posters.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.
Early-career cardiologists and researchers face a complex landscape: they must navigate the increasing clinical complexity of cardiovascular disease, stay abreast of rapid scientific developments and manage the pressures of clinical, academic and personal responsibilities. Recognising the need for greater support, ...
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
In this engaging short animation, learn how cholesterol-lowering MTP inhibitors act to reduce cholesterol in people with homozygous familial hypercholesterolemia, and explore clinical data supporting their long-term hepatic safety.
touchCARDIO is delighted to announce that Heart International has received an impressive new Impact Factor of 1.9 in the 2024 Journal Citation Reports (JCR). This achievement marks a notable increase from last year’s Impact Factor of 0.2 and highlights the journal’s growing influence in the cardiology field.
Despite improved treatment of atherosclerotic cardiovascular disease, coronary artery disease (CAD) remains the leading cause of death and disability worldwide.1Â Treatment of traditional risk factors, mainly low-density lipoprotein (LDL) cholesterol, is the foundation of atherosclerotic risk reduction. However, a considerable ...
Dr Jacob White is an interventional radiologist with over 15 years of experience. He currently serves as Medical Director at USA Vein Clinics, Vascular and Fibroid Centers and is on staff at the Jacobi Medical Centre in NYC. Dr White is ...
The TRANSLATE-TIMI 70 trial looks at the effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol. touchCARDIO spoke with Dr Brian Bergmark (Brigham and Women's Hospital, Boston, MA) about the use of vupanorsen and the safety ...
The CANTOS trial assessed the differential impact of residual inflammatory risk and residual cholesterol risk among atherosclerosis patients with and without chronic kidney disease. touchCARDIO spoke to Prof Paul Ridker (Harvard University, Boston, MA, USA) to discuss his presentation at ...
Prof. Charalambos Antoniades (Professor of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK) kindly shared his thoughts on the fat attenuation index and its use in clinical decision making from the virtual ESC Congress 2021. Questions Can you ...
Prof. Charalambos Antoniades (Professor of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK) kindly shared his thoughts on the use of high-sensitivity C-reactive protein as a biomarker in clinical decision making, and the role of perivascular adipose ...
Prof. Stephen Nicholls (Professor of Cardiology, Monash University, Melbourne, Australia) kindly shared his thoughts on the impact of PCSK9 inhibitors on lipid-lowering therapy, the effects of statins on coronary atherosclerotic plaques and the HUYGENS study from the virtual ESC Congress 2021. ...
Peripheral artery disease (PAD) is a severe manifestation of systemic atherosclerotic disease that commonly refers to lower-extremity arterial involvement. The global burden of PAD is estimated to involve over 200 million patients, with prevalence increasing by 24% over the past decade.1 In ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
